Review Article

Role of PPARs in Progression of Anxiety: Literature Analysis and Signaling Pathways Reconstruction

Olga I. Rudko,1,2 Artemii V. Tretiakov,1,2 Elena A. Naumova,1,2 and Eugene A. Klimov1,2

1Faculty of Biology, Lomonosov Moscow State University, Moscow 119234, Russia
2Sirius University of Science and Technology, Sochi 354340, Russia

Correspondence should be addressed to Eugene A. Klimov; klimov_eugeney@mail.ru

Received 17 September 2020; Revised 26 October 2020; Accepted 17 November 2020; Published 30 November 2020

Academic Editor: Hongbao Cao

Copyright © 2020 Olga I. Rudko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peroxisome proliferator-activated receptor (PPAR) group includes three isoforms encoded by PPARG, PPARA, and PPARD genes. High concentrations of PPARs are found in parts of the brain linked to anxiety development, including hippocampus and amygdala. Among three PPAR isoforms, PPARG demonstrates the highest expression in CNS, where it can be found in neurons, astrocytes, and glial cells. Herein, the highest PPARG expression occurs in amygdala. However, little is known considering possible connections between PPARs and anxiety behavior. We reviewed possible connections between PPARs and anxiety. We used the Pathway Studio software (Elsevier). Signal pathways were created according to previously developed algorithms. SNEA was performed in Pathway Studio. Current study revealed 14 PPAR-regulated proteins linked to anxiety. Possible mechanism of PPAR involvement in neuroinflammation protection is proposed. Signal pathway reconstruction and reviewing aimed to reveal possible connection between PPARG and CCK-ergic system was conducted. Said analysis revealed that PPARG-dependent regulation of MME and ACE peptidase expression may affect levels of nonhydrolysed, i.e., active CCK-4. Impairments in PPARG regulation and following MME and ACE peptidase expression impairments in amygdala may be the possible mechanism leading to pathological anxiety development, with brain CCK-4 accumulation being a key link. Literature data analysis and signal pathway reconstruction and reviewing revealed two possible mechanisms of peroxisome proliferator-activated receptors involvement in pathological anxiety: (1) cytokine expression and neuroinflammation mechanism and (2) regulation of peptidases targeted to anxiety-associated neuropeptides, primarily CCK-4, mechanism.

1. Introduction

1.1. Anxiety and Anxiety Disorders. Anxiety disorders (including generalized anxiety disorders or panic disorders) are the most widespread mental diseases which are at the same time difficult to treat [1, 2]. Main characteristic of panic disorder is presence of repetitive sudden panic attacks [3]. According to large scale surveys, percentage of population suffering from the anxiety disease throughout lifetime is up to 33.7% [4, 5].

Many researchers report that anxiety disorders cause even more severe decrease in patient’s quality of life and psychosocial functions than other chronic diseases including diabetes, cardiovascular diseases, and lung diseases [6–8]. Both environmental factors and genetic factors are believed to be involved in the development of panic disorders [9, 10].

Last decade studies showed that anxiety and anxiety disorder are associated with amygdala functioning and various types of its dysfunction that lead to a decrease in its activity [11–15]. Hypothalamus is also often associated with anxiety [16, 17]. Thus, it was shown that the anorexigenic neuropeptide CCK4 is able to directly interact with the hypothalamus [18].

Most modern studies of the molecular basis underlying F40-F48 series (ICD-10) mental disorders focus on polymorphisms in genes encoding the main neurotransmitter system proteins, i.e., catecholamine and GABAergic [19]. However, it is already clear that they are not the primary link in the fine
regulation of the formation, severity, and direction of anxious emotions.

1.2. Peroxisome Proliferator-Activated Receptors. Peroxisome proliferator-activated receptor (PPAR) subfamily belongs to nuclear receptor family. Three isoforms encoded by individual genes are known: PPARγ, PPARα, and PPARδ. PPARs are ligand-dependent transcription factors that regulate target gene expression by binding to specific peroxisome proliferator response elements (PPREs) in the enhancer sites of regulated genes. Each receptor binds to its PPRE as a heterodimer with a retinoid X receptor (RXR). Upon binding of the agonist, PPAR conformation changes and stabilizes, after which transcriptional coactivators contribute to activation of target genes [20].

The PPARs possess the canonical domain structure common to other nuclear receptor family members, including the amino-terminal AF-1 transactivation domain, followed by a DNA-binding domain and a dimerization and ligand binding domain with a ligand-dependent transactivation function AF-2 located at the carboxy-terminal region [21].

PPARs regulate expression of genes actively involved in lipid and carbohydrate metabolism, vascular homeostasis, tissue repair, cell proliferation and differentiation, and sexual dimorphism [22].

PPARs are expressed in almost all mammalian tissues and organs. The expression patterns of PPARα, PPARβ/δ, and PPARγ differ, although intersections do occur. A high expression level of all PPARs is observed in tissues with active fatty acid metabolism. PPARβ/δ is constitutively expressed in almost all tissues [22, 23]. PPARγ among all 3 isoforms has the highest expression in the nervous system, where it was found in neurons, astrocytes, and glial cells [24]. Moreover, all three PPA receptors are expressed both in amygdala and in the hypothalamus [24]. PPAR association with various diseases is also shown [25]. However, the association with anxiety is poorly understood.

This study for the first time analyzes the relationship between PPARs and anxiety. Our results will allow to look at molecular-genetic basis of anxiety disorders pathogenesis, underlying mechanisms and related problems from a new angle.

2. Materials and Methods

We used the Pathway Studio® 9 desktop software with ResNet® 14 database and web version of the Pathway Studio software (https://mammalcedfx.pathwaystudio.com) (Elsevier). Additional search of information was performed by using PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), TargetInsights (https://demo.elseviertextmining.com/), and Google Scholar (https://scholar.google.ru/). Signal pathways were created according to previously developed algorithms [26].

Search algorithm and workflow scheme are presented in Figure 1. Detailed description is given along in Results for better understanding.

3. Results and Discussion

3.1. A Search for Common PPARs and Anxiety Targets. During the first step of our work, we used text-mining and signaling pathway analysis for revealing possible role of PPARs in the development of anxiety.

We used the Pathway Studio® 9 desktop software with ResNet® 14 database and web version of the Pathway Studio software (https://mammalcedfx.pathwaystudio.com) (Elsevier).
The search algorithm for anxiety-protein-PPAR links was as follows:

1. Searching proteins linked to anxiety through concentration change. Linkage type: QuantitativeChange was used in Pathway Studio. This type allows to search for proteins with reported concentration alterations in patients with anxiety. Total of 304 proteins were found.

2. 304 proteins discovered on the previous step were taken into further analysis by searching linkage between protein and each of the three PPARs independently. We had chosen to search for PPAR connections separately to avoid too complicated pathways. Linkage types: Expression and Promoter-Binding were used in Pathway Studio. These two types imply direct PPAR effect on protein concentration through promoter binding or other direct interaction which makes them the most relevant.

3. On the next step, all the supporting references were manually revised; first by reviewing Pathway Studio text-mined "Sentences" section, and after that, if necessary, by studying the whole text for additional details.

4. This analysis resulted in three schemes which include all the proteins linked to both anxiety and PPARs. Each scheme was representing one PPAR isoform.

5. Three schemes created on the previous step were combined into one for better data representation and reducing number of figures.

For describing proteins and their role, search engines highlighted in Materials and Methods were used. Thus, lists of proteins with confirmed quantity changes in anxiety, and proteins connected to PPARs were obtained. Figure 2 and Table 1 show combined target lists.

3.2. Common Target Descriptions and Possible Underlying Mechanisms. Only cytokines (IFNG, IL6, and TNF) and vascular endothelial growth factor A (VEGFA) are regulated by all three PPARs. In most cases, connection to PPARα is present. In one case, HSD11B2, only connection to PPARD is present. Thus, 14 PPAR-regulated proteins with altered concentration in anxiety are known:

3.2.1. BDNF (Brain-Derived Neurotrophic Factor). Protein’s main function is nerve growth and neuron homeostasis [27]. Both BDNF polymorphisms and concentration alterations are linked to variety of mental and neurological diseases [28]. In our case, reduced BDNF product concentration is observed in both animal models ([29], see supplementary) and patients ([30], see supplementary).

The BDNF expression is positively regulated by PPARA ([31], see supplementary) and PPARG ([32], see supplementary). If PPARs-independent BDNF expression regulation pathways are unaltered, lower PPARA and PPARG levels are to be expected as well.

3.2.2. CREB1 (CAMP Responsive Element Binding Protein 1). This is a transcription factor which induces target gene transcription in response to hormonal stimulation via the cAMP pathway. This protein is involved in many cellular processes and is expressed in all tissues (https://www.ncbi.nlm.nih.gov/gene/1385). CREB1 activity is important for brain neuron development and maintenance [33, 34]. Thus, its linkage to mental diseases’ pathogenesis is widely studied [35, 36]. The CREB1 expression is known to be lowered in animal models of anxiety [37, 38]. PPARA and PPARG activate CREB1 transcription by binding to its promoter. Exact in-promoter targets of PPARA are known [39, 40], which points out its important role on CREB1 regulation. PPARG was shown to be able to bind to CREB1 promoter bearing certain nucleotide sequence and block its expression [41]. However, other mechanisms leading to CREB1 activation along with...
PPARG activation are known, i.e., PKCA (protein kinase C, alpha) activation with further CREB1 activation [42]. Interestingly, CREB1 activation via cAMP-PKCA signaling provokes binding of CREB1 to a cAMP responsive element-like site in PPARG gene promoter region [43] which allows to speculate of mutual regulation of these factors.

3.2.3. CRP (C-Reactive Protein). This protein is involved in several host defence-related functions based on its ability to recognize foreign pathogens and damaged host cells and initiate their elimination by interacting with humoral and cellular effector systems in the blood (https://www.ncbi.nlm.nih.gov/gene/1401). CRP linkage to anxiety was shown in several studies. Patients with anxiety were shown to have increased CRP levels [44–46], wherein all authors point out the alterations in patients' immune status. This can be explained by possible interactions between the central nervous system and the immune system in neuropsychiatric disorders. CRP regulation via PPARs is negative in both PPARA ([47, 48], see supplementary) and PPARG ([49, 50], see supplementary) cases. There is no information on PPARD-CRP interactions. Thus, in case of anxiety, we can observe an increase of CRP levels despite PPARA and PPARG blocking it. The reasons may lie in either other CRP activation signal pathways or tissue effects insofar CRP is expressed in the liver. This is the only protein in this list which lacks expression brain regions of interest.

3.2.4. FOS. FOS proteins are members of the transcription factor complex AP-1. FOS proteins were implicated as cell proliferation, differentiation, and transformation regulators. FOS gene is expressed in almost every tissue (https://www.ncbi.nlm.nih.gov/gene/2353). One of the most thorough research of this gene is focused on neuronal plasticity [51, 52]. Animal models of anxiety, fear, and depression show increased FOS in the brain areas linked to the formation of these behavioral reactions in animals [53–55]. Negative effect of PPARA activation on the FOS expression is known [56, 57]. It is also known that PPARG regulates the FOS expression [58–61], but there is no univocal opinion wherever this regulation is positive or negative. It is most likely that several signal pathways involving PPARG and FOS are present. Most of the PPARG-FOS interaction studies are using osteogenesis models, which makes it impossible to

| Protein | Full name | Functional class | PPARs |
|---------|-----------|-----------------|-------|
| BDNF    | Brain derived neurotrophic factor | Growth factor | PPARA PPARG |
| CREB1   | cAMP responsive element binding protein 1 | Class bZIP transcription factor | PPARA PPARG |
| CRP     | C-reactive protein | Plasma protein | PPARA PPARG |
| FOS     | FOS proto-oncogene, AP-1 transcription factor subunit | Class bZIP transcription factor | PPARA PPARG |
| HSD11B2 | Hydroxysteroid 11-beta dehydrogenase 2 | Steroid metabolism protein | PPARD |
| IFNG    | Interferon gamma | Inflammatory cytokine | PPARD PPARG |
| IL6     | Interleukin 6 | Inflammatory cytokine | PPARD PPARG |
| LEP     | Leptin | Adipokine | PPARD PPARG |
| NPY     | Neuropeptide Y | Neuropeptide | PPARG |
| NR3C1   | Nuclear receptor subfamily 3 group C member 1 | Nuclear steroid hormone receptor family | PPARA |
| PRL     | Prolactin | Glycopeptide hormone (gonadotropins) | PPARA |
| TNF     | Tumor necrosis factor | Inflammatory cytokine/adipokine | PPARA PPARD PPARG |
| TSPO    | Translocator protein | Mitochondrial damage protein | PPARA |
| VEGFA   | Vascular endothelial growth factor A | Growth factor | PPARA PPARD PPARG |

Table 1: List of 14 anxiety-associated proteins–targets of PPARs.
speculate about PPARs-FOS-anxiety linkage. This linkage is
the least evidence-supported among this list.

3.2.5. HSD11B2. The corticosteroid 11-beta-dehydrogenase
is a microsomal enzyme complex responsible for the inter-
conversion of glucocorticoid cortisol and its inactive metab-
olite cortisone; this conversion prevents illicit activation of
the mineralocorticoid receptor (https://www.ncbi.nlm.nih.
gov/gene/3291). Cortisol is intrinsically linked to anxiety as
increases in its concentration correlates with anxiety and its
symptoms [62, 63]. Insofar, as HSD11B2 enzyme is directly
involved in processes related to cortisol, its role is patho-
genesis of diseases characterized by increased cortisol levels
is important [64]. Animal models with HSD11B2 gene knock-
out have inborn predisposition to increased anxiety [65].
Thus, reduced HSD11B2 activity leads to increased cortisol
and anxiety phenotype development. Main organs expressing
HSD11B2 are the kidneys, intestines, and salivary glands.
Only three of PPAR receptors regulate the HSD11B2 expres-
sion wherein this regulation is negative. PPARD is known to
bind to HSD11B2 promoter in trophoblasts of the placenta
and inhibits its expression [66–68]. We have no knowledge
of studies describing PPARD and HSD11B2 interactions in
other tissues. However, as far as PPARD is expressed in all
tissues, both genes are expressed in the kidney which is the
most interesting organ from the point of cortisol accumula-
tion. Thus, in case of HSD11B2, one of peroxisome
proliferator-activated receptors (PPARD) may be linked to
one of the clinical anxiety manifestations, i.e., increased
cortisol.

3.2.6. IFNG. Interferon gamma is soluble cytokine that is a
member of the type II interferon class, secreted by cells of
both the innate and adaptive immune systems (https://www
.ncbi.nlm.nih.gov/gene/3458). Its expression is limited by
immune system cells. Interferon gamma may modulate anxi-
ety and depressive states via its role in brain plasticity [69].
Other study suggests that decreased INFG in patients with
anxiety disorder is not a cause but a result of the disease
[70]. However, all PPARs regulate its expression negatively
via INFG promoter binding and blocking its transcriptional
activity ([71–75], see supplementary). Thus, link between
PPARs and INFG regulation is unequivocal, but determining
if decreased INFG concentration is a disease’s cause, or a
consequence is a subject for further studies. It is possible that
decrease of INFG concentration is a result of prolonged
anxiety.

3.2.7. IL6 (Interleukin 6). This cytokine plays role in inflam-
matation and maturation of B cells; encoded protein was
shown to be an endogenous pyrogen capable of inducing
fever in people with autoimmune diseases or infections
(https://www.ncbi.nlm.nih.gov/gene/3569). Increase of the
IL6 expression in patients with anxiety/depression is well
known [76–80]. However, some studies show decrease of
IL6 levels in states characterized by pathological anxiety
[81, 82]. Thus, IL6 anxiety link is possible but requires
further studies. All three PPARs negatively regulate IL6
([83–85], see supplementary). Further understanding PPARs
and IL6 interaction requires evaluation of IL6 role in anxiety.

3.2.8. LEP. Leptin is secreted by white adipocytes into the cir-
culation and plays a major role in the regulation of energy
homeostasis; it binds to the leptin receptor in the brain,
which activates downstream signaling pathways that inhibit
feeding and promote energy expenditure (https://www.ncbi
.nlm.nih.gov/gene/2908). Leptin concentration is increased
in patients with emotional anxiety and reaches its peak in
conditions of moderate anxiety [86]. Other studies also show
high levels of leptin which correlates with anxiety levels
[87–89]. Leptin administration resulted in dose-dependent
anxiety decrease [86, 90]. This data points out the positive
link between leptin and anxiety. Among three PPARs, two
receptors regulate LEP gene expression, i.e., delta and
gamma. PPARD binds to the LEP promoter and inhibits its
expression [91–93]. Thus, one of the mechanisms of leptin
increase in anxiety may be linked to PPARD and PPARG
decrease.

3.2.9. NPY. Neuropeptide Y is a neuropeptide that is widely
expressed in the central nervous system and influences many
physiological processes, including cortical excitability, stress
response, food intake, circadian rhythms, and cardiovascular
function (https://www.ncbi.nlm.nih.gov/gene/4852). Neuro-
peptide Y deficiency is significantly linked to anxiety devel-
opment in all animals including fish and human ([94–97],
see supplementary). The NPY expression is linked to only
one PPAR—gamma; its positive effect on the NPY expression
is known in arcuate hypothalamus [98]. We can speculate
that NPY decrease may be linked to alterations in PPARG
activation/functioning.

3.2.10. NR3C1. Glucocorticoid receptor can function both as
a transcription factor that binds to glucocorticoid response
elements in the promoters of glucocorticoid responsive genes
to activate their transcription and as a regulator of other tran-
scription factors and involved in inflammatory responses,
cellular proliferation, and differentiation in target tissues
(https://www.ncbi.nlm.nih.gov/gene/2908). Increase of the
NR3C1 expression was linked to anxiety increases in rats
[99]; antagonist administration resulted in reduction of
anxiety-like behavior in rats [100]. Increased glucocorticoid
leads to increased anxiety via activation of receptor NR3C1
[101, 102]. Among all peroxisome proliferator-activated
receptors, only PPARA is linked to the NR3C1 expression
regulation as it reduces it [103–105]. Wherein mutual gene
regulation is known as NR3C1 is capable of activating the
PPARA expression [106]. Thus, PPARA is capable of regulat-
ing NR3C1-dependent anxiety.

3.2.11. PRL. Prolactin is a hormonal growth regulator for
many tissues, including cells of the immune system, essential
for lactation (https://www.ncbi.nlm.nih.gov/gene/5617). An
increase in prolactin levels is associated with anxiety in
women during lactation [107], as well as in paratroopers
before jumping [108]. In roman low-avoidance rats with an
increased level of anxiety, an increased level of the PRL gene
expression in the amygdala was shown [109]. PPARA is the
only PPAR able of activating the PRL expression [110–112]. It is also noted that gene is not necessarily activated via PPARA binding to PRL promotor [111, 113]. Thus, one of the mechanisms leading to the increased PRL in anxiety may be explained due to PPARA activity.

3.2.12. TNF. Tumor necrosis factor is a multifunctional pro-inflammatory cytokine that belongs to the tumor necrosis factor superfamily; it is mainly secreted by macrophages and involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation (https://www.ncbi.nlm.nih.gov/gene/7124). Serum TNF levels are elevated in patients with anxiety symptoms [114], as well as in patients with generalized anxiety disorder [115]. TNF knock-out mice showed a low level of anxiety [116]. Cited works indicate a reliable association of TNF elevation with anxiety. All three PPARs block the expression of TNF, as well as the rest of the cytokines identified in our work ([92, 117–121], see supplementary for additional links). Thus, the explanation of increased TNF in anxiety patients lays either in the malfunction/decreased activity of PPARs or in the activation of another mechanism for regulating the TNF expression.

3.2.13. TSPO. Translocator protein is a key factor in the flow of cholesterol into mitochondria to permit the initiation of steroid hormone synthesis and interacts with some benzodiazepines (https://www.ncbi.nlm.nih.gov/gene/706). The level of TSPO was significantly reduced in both patients with anxiety and anxiety mice models [122–125] and increased after treatment [126]. Since the benzodiazepines are used in the treatment of anxiety and anxiety disorder [127], the association of their molecular target TSPO with anxiety is beyond doubt. The TSPO expression is negatively regulated by PPARA ([128, 129], see supplementary). It can be assumed that PPARA activity may adversely affect the development of anxiety due to a decrease in the TSPO expression.

3.2.14. VEGFA (Vascular Endothelial Growth Factor A). It is a growth factor which induces proliferation and migration of vascular endothelial cells; essential for angiogenesis (https://www.ncbi.nlm.nih.gov/gene/7422). A decrease in VEGFA concentration in patients with anxiety [130, 131] and a high VEGFA level accompanying low anxiety [30] were reported. The VEGFA expression is regulated by all PPARs: delta and gamma bind to the promoter, activating the translation ([132], see supplementary), alpha, on the contrary, blocks VEGFA promoter, reducing expression ([133], see supplementary). Thus, activation and blockade of the VEGFA gene expression are also regulated by transcription factor PPARs. Since the VEGFA expression is reduced in patients with increased anxiety, it can be assumed that in this case, both PPARA activation and a decrease in PPAR delta and gamma activity may occur. Table 2 summarizes above said.

In our analysis, two groups of proteins are the most presented:

(i) Inflammatory cytokines—three members (IL6, INFG, and TNF)

(ii) Transcription factors—three members (CREB1, FOS, and NR3C1)

Interestingly, all PPARs are linked to the inflammatory cytokine expression, while only PPARA and PPARG are involved linked to transcription factor expression. Transcriptional targets of PPARD are involved in immune response and body homeostasis (HSD11B2, LEP, and VEGFA). It expresses in all brain tissues at the same level [24], which indicates the probable absence of its participation in the development of most behavioral reactions, including anxiety.

3.3. PPARs, Common Target, and Amygdala. Proteins, identified in the previous step, were reviewed for expression in amygdaloid:

(1) Amygdaloid was added to the list, and all the amygdaloid-protein links were extracted

(2) All the links except for CellExpression type were excluded

(3) All the supporting references were manually revised at first by reviewing Pathway Studio text-mined “Sentences” section, and after that, if necessary, by studying the whole text for additional details

All detected proteins, except for CRP (C-reactive protein), are expressed in amygdala (Figure 3). Information about the environment is acquired via sensory organs and is transferred to the thalamus nuclei of the limbic system and then to the cortical sections of the sensory analyzer (auditory, visual, tactile cortex):

(i) The limbic system responds to the image that the brain has perceived and recognized. In particular,
the brain, while alpha and gamma show selective expression: and fear [13, 134, 135].

part of the brain responsible for the formation of anxiety

3.4. Enrichment Analysis. To further elucidate role of PPARs
in the formation of anxiety, including those that are widely
high concentration are located in the brain areas involved

Figure 3: The association of proteins with amygdala. Relation
type—CellExpression.

Thus, the amygdala is currently defined as the main part of the brain responsible for the formation of anxiety and fear [13, 134, 135].

PPARs and retinoid X receptor are expressed in the central nervous system. Delta is widely expressed in all parts of the brain, while alpha and gamma show selective expression:

(i) Gamma is not expressed in the structures of the olfactory bulb, in the part of the olfactory cortex, part of the neocortex, some structures of the thalamus, nuclei of the solitary tract, dorsal motor nuclei of the vagus, and Purkinje cells

(ii) Alpha is not expressed in the hypothalamus [24]

All 3 isoforms are actively expressed in the basal ganglia to which amygdala belongs [24, 136, 137]. Thus, PPARs in high concentration are located in the brain areas involved in the formation of anxiety, including those that are widely represented in the hippocampus and amygdala.

3.4. Enrichment Analysis. To further elucidate role of PPARs in anxiety, we conducted Sub-Network Enrichment Analysis (SNEA) using the Pathway Studio® software using list of genes obtained during the first stage of our study. We found considerable number of pathways/gene sets in almost every search subgroup (SNEA: for compounds regulators (branch-drugs), for compounds regulators, for phenotypes and processes (all), with anatomy, with expression regulators) for every gene associated with anxiety disorder.

Table 3 lists top 10 of 100 substances obtained after the SNEA Compounds Regulators Enriched analysis. Compound regulators were chosen as the most representative search subgroup. All these substances (ginsenoside, epinephrine, corticosterone, norepinephrine, Li+, serotonin, n-3 polyunsaturated fatty acid, dehydroepiandrosterone), either have an antistress, antidepressant, neuroprotective, and neurogenic effects or regulate blood pressure, carbohydrate, and lipid metabolism (according to https://pubchem.ncbi.nlm.nih.gov/). Some of them are found in cellular membranes and blood vessel walls. Despite the low Jaccard similarity, which may be explained by relatively low number of searched genes (17), according to enrichment analysis, good ratio of 9/10 of Gene Set Seed related to neurological regulation is observed. This means that 9 substances out of 10 are related to neurological regulation through underlying pathways. This result points out the significant role these genes play in pathogenesis of psychoneurological diseases.

In this set of 10 substances, genes BDNF, FOS, VEGFA, IFNG, IL6, TNF, and PPAR (A, D, G) are present in 100% of underlying pathways. PPARG is present in 80% of them, while PPARA in 70% cases and PPARD in 50%. This tendency is persist in full list of 100 substances obtained after SNEA Compounds Regulators Enriched analysis with BDNF presence in 77%; FOS, 76%; VEGFA, 82%; IFNG, 76%; IL6, 96%; TNF, 96%; and PPAR (A, D, G), 78%. Among PPARs, PPARA is present in 52% and PPARD in 27%; most presented is PPARG in 71%, wherein only 18% out of 100 substances lack any PPARs in their underlying pathway.

This result is an indirect evidence of PPAR role in the anxiety development.

3.5. Neuroinflammation, PPARs, and Anxiety. Recently, the theory of neuroinflammation as the cause of anxiety development was discussed [138–141]. We performed a signal pathway analysis which revealed possible mechanism explaining the role of PPARs in the development of neuroinflammation (Figure 4).

Signal pathway schemes were designed manually using data available in the ResNet database describing links between objects. Annotated schemes available in the Pathway Studio software were used as well.

We suggest that ligand-activated PPARs block the activity of the NF-kappa B family of transcription factors [142, 143]. Coactivators of PPARs-retinoid-X receptor subfamily [144] and PPARG coactivator 1 alpha (PPARGC1A) [145] are also involved in this process. NF-kappa B activates the transcription of number of proinflammatory cytokines, including those that change their expression during anxiety, i.e., IL6 [146], TNF [147], and IFNG [148]. Thus, PPARs normally block the development of neuroinflammation [149, 150].

3.6. Peroxisome Proliferator-Activated Receptor Gamma (PPARG) and Cholecystokininergic Systems in Anxiety. In recent years, PPARG was shown to be involved in the development of pathological anxiety [151–153]. This surge of
research was initiated by Domi et al., whose aim was to study the role of PPARG in the regulation of GABAergic transmis-
sion [154]. The work revealed the role of PPARG in the regula-
tion of mood disorders, indicating that weakened signal transmis-
sion can contribute to exacerbation of anxiety and the negative ef-
facts of stress. Authors suggest that activation of PPARG may be useful in the treatment of psychiatric conditions related to stress and, in particular, anxiety disorders [154].

At the same time, PPARG is most actively expressed in the amygdala [154–158].

Cholecystokinin (CCK) is a neuropeptide which may be found in high concentrations throughout the central nervous system, where it is involved in numerous physiological functions [159]. The role of CCK, especially its smallest func-
tional peptide, CCK-4, in the induction and maintenance of anxiety and major depression is well known [160–162]. The increase in CCK-4 is associated with loss of motivation, anxiety, and panic attacks [159, 163, 164].

The amygdala is firmly connected with the cholecystokin-
nergic system. It was shown that CCK-4 is synthesized and released into amygdala, hippocampal formation, and cerebral cortex [165, 166]. Both CCK-4 receptors are expressed in the amygdala: CCKAR [167, 168] and CCKBR [168, 169].

In this part of the work, we carried out an analysis of signaling pathways in order to identify a possible connection between the cholecystokininergic system and PPARG. We used the Pathway Studio® 9 desktop software with the ResNet®14 database and web version of the Pathway Studio software (https://mammalcedfx.pathwaystudio.com)
Signal pathways were created according to the algorithms we developed [170]. The results are presented in Figure 5 and are described below.

PPARG and PPARGC1A are involved in MME transcription regulation [171]. Simultaneously, PPARG inhibits the ACE expression [172].

CCK-4 hydrolysis (Trp-Met-Asp-Phe = WMDF) may be carried out by two enzymes: membrane metalloendopeptidase (MME, also known as NEP, EC 3.4.24.11) and angiotensin I converting enzyme (ACE, EC 3.4.15.1) [173]. MME and ACE cut 2 terminal amino acids (DF) from CCK-4 and CCK-8 which leads to forming of unfunctional peptides (or dipeptides WM and DF in case of CCK-4) [174, 175].

Thus, PPARG-related MME and ACE expression regulation affect levels of active nonhydrolysed CCK-4. Dysregulation of PPARG and the following alteration of peptidase expression in amygdala may be a possible mechanism of pathological anxiety development, with a CCK-4 accumulation as a main cause. This may explain Domi et al. results [154].

4. Conclusions

We examined possible associations of PPARs with anxiety. An analysis of the data and signaling pathways available in the literature suggests two mechanisms for the participation of peroxisome proliferator-activated receptors in the formation of anxiety: (1) expression of cytokines and neuroinflammation and (2) regulation of the expression of peptidases, the targets of which are neuropeptides associated with anxiety (CCK-4 in the first place). Further research in these areas will help to better understand the role of PPARs in the development of anxiety.

Data Availability

All supplemental materials (Excel file) are available to download from ResearchGate resource by the link https://www.researchgate.net/publication/340418909_Supplemental_Materials_Role_of_PPARs_in_progression_of_anxiety. Additional data is available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

The reported study was funded by RFBR, project number 19-34-51045.

Supplementary Materials

The supplement file was provided for this study (an excel file), including following information: PPARs and neuroinflammation relation sheet, PPARs and CCK4 relation sheet, PPARs and anxiety common target sheet, and amygdaloid expressed gene sheet. The data on relations between objects on pathways. The downloadable online version can be accessed via ResearchGate: https://www.researchgate.net/publication/340418909_Supplemental_Materials_Role_of_PPARs_in_progression_of_anxiety. (Supplementary Materials)

References

[1] D. J. Kupfer, “Anxiety and DSM-5,” Dialogues in Clinical Neuroscience, vol. 17, no. 3, pp. 245-246, 2015.
[2] F. Thibaut, “Anxiety disorders: a review of current literature,” Dialogues in Clinical Neuroscience, vol. 19, no. 2, pp. 87-88, 2017.
[3] C. Cackovic, S. Nazir, and R. Marwaha, “Panic disorder (attack),” in StatPearls, StatPearls Publishing, Treasure Island, FL, USA, 2020.
schizophrenia," *Frontiers in Molecular Neuroscience*, vol. 11, p. 255, 2018.

[36] C. Yu, Y. X. Bai, X. P. Xu et al., "Behavioral abnormality along with NMDAR-related CREB suppression in rat hippocampus after shortwave exposure," *Biomedical and Environmental Sciences*, vol. 32, no. 3, pp. 189–198, 2019.

[37] M. Barrot, D. L. Wallace, C. A. Bolaños et al., "Regulation of anxiety and initiation of sexual behavior by CREB in the nucleus accumbens," *Proceedings National Academy of Sciences United States of America*, vol. 102, no. 23, pp. 8357–8362, 2005.

[38] T. Rubino, C. Guidali, D. Vigano et al., "CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour," *Neuropharmacology*, vol. 54, no. 1, pp. 151–160, 2008.

[39] A. Roy, M. Jana, G. T. Corbett et al., "Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor α," *Cell Reports*, vol. 4, no. 4, pp. 724–737, 2013.

[40] A. Roy and K. Pahan, "PPARα signaling in the hippocampus: crosstalk between fat and memory," *Journal of Neuroimmune Pharmacology*, vol. 10, no. 1, pp. 30–34, 2015.

[41] C. Sharma, A. Pradeep, R. G. Pestell, and B. Rana, "Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes," *The Journal of Biological Chemistry*, vol. 279, no. 17, pp. 16927–16938, 2004.

[42] J. Vamecq, J.-M. Colet, J. J. Vanden Eynde, G. Briand, N. Porchet, and S. Rocchi, "PPARs: interference with Warburg’ effect and clinical anticancer trials," *PPAR Research*, vol. 2012, Article ID 304760, 23 pages, 2012.

[43] X. He, J.-L. Hu, J. Li et al., "A feedback loop in PPARγ-adenosine A2A receptor signaling inhibits inflammation and attenuates lung damages in a mouse model of LPS-induced acute lung injury," *Cellular Signalling*, vol. 25, no. 9, pp. 1913–1923, 2013.

[44] R. Hou, G. Ye, Y. Liu et al., "Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder," *Brain, Behavior, and Immunity*, vol. 81, pp. 105–110, 2019.

[45] T. Liukkonen, P. Räsänen, J. Jokelainen et al., "The association between anxiety and C-reactive protein (CRP) levels: results from the Northern Finland 1966 birth cohort study," *European Psychiatry*, vol. 26, no. 6, pp. 363–369, 2011.

[46] C. Pittavos, D. B. Panagiotakos, C. Papageorgiou, E. Tsetsekou, C. Soldatos, and C. Stefanadis, "Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study," *Atherosclerosis*, vol. 185, no. 2, pp. 320–326, 2006.

[47] M. C. Cave, H. B. Clair, J. E. Hardesty et al., "Nuclear receptors and nonalcoholic fatty liver disease," *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms*, vol. 1859, no. 9, pp. 1083–1099, 2016.

[48] M. H. Davidson and P. P. Toth, "Comparative effects of lipid-lowering therapies," *Progress in Cardiovascular Diseases*, vol. 47, no. 2, pp. 73–104, 2004.

[49] A. Laudisio, M. R. Lo Monaco, D. L. Vetrano et al., "Association of metabolic syndrome with falls in patients with Parkinson’s disease," *Clinical Nutrition*, vol. 36, no. 2, pp. 559–563, 2017.

[50] J. Plutzky, "Peroxisome proliferator-activated receptors as therapeutic targets in inflammation," *Journal of the American College of Cardiology*, vol. 42, no. 10, pp. 1764–1766, 2003.

[51] F. T. Gallo, C. Katche, J. F. Morici, J. H. Medina, and N. V. Weissstaub, "Immediate early genes, memory and psychiatric disorders: focus on c-Fos, Egr1 and Arc," *Frontiers in Behavioral Neuroscience*, vol. 12, p. 79, 2018.

[52] J. Jaworski, K. Kalita, and E. Knapska, "c-Fos and neuronal plasticity: the aftermath of Kaczmarek’s theory," *Acta Neurobiologiae Experimentalis (Wars)*, vol. 78, no. 4, pp. 287–296, 2018.

[53] C. E. O’Neill, R. J. Newsom, J. Stafford et al., "Adolescent caffeine consumption increases adulthood anxiety-related behavior and modifies neuroendocrine signaling," *Psychoneuroendocrinology*, vol. 67, pp. 40–50, 2016.

[54] L. G. Staples, "Predator odor avoidance as a rodent model of anxiety: learning-mediated consequences beyond the initial exposure," *Neurobiology of Learning and Memory*, vol. 94, no. 4, pp. 435–445, 2010.

[55] B. Xiao, F. Han, H.-T. Wang, and Y.-X. Shi, "Single-prolonged stress induces increased phosphorylation of extracellular signal-regulated kinase in a rat model of post-traumatic stress disorder," *Molecular Medicine Reports*, vol. 4, pp. 445–449, 2011.

[56] C.-B. Li, X.-X. Li, Y.-G. Chen et al., "PPARγ agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes," *Diabetes*, vol. 56, no. 6, pp. 1662–1670, 2007.

[57] S. Lim, C. J. Jin, M. Kim et al., "PPARγ gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 4, pp. 808–813, 2006.

[58] A. Nakanishi and I. Tsukamoto, "n-3 polyunsaturated fatty acids stimulate osteoclastogenesis through PPARα-mediated enhancement of c-Fos expression, and suppress osteoclastogenesis through PPARγ-dependent inhibition of NFκB activation," *The Journal of Nutritional Biochemistry*, vol. 26, no. 11, pp. 1317–1327, 2015.

[59] Y. Wan, L.-W. Chong, and R. M. Evans, "PPAR-gamma regulates osteoclastogenesis in mice," *Nature Medicine*, vol. 13, no. 12, pp. 1496–1503, 2007.

[60] Y.-X. Wu, Y. Sun, Y.-P. Ye et al., "Iguratimod prevents ovarioctomy-induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator-activated receptor-γ," *Molecular Medicine Reports*, vol. 16, no. 6, pp. 8200–8208, 2017.

[61] A. Bierckx, G. Dieleman, J. H. M. Tulen et al., "Persistence of anxiety disorders and comonitant changes in cortisol," *Journal of Anxiety Disorders*, vol. 26, no. 6, pp. 635–641, 2012.

[62] S. Fischer and A. J. Cleare, "Cortisol as a predictor of psychiatric relapse in patients with major depression and generalized anxiety disorder," *Journal of Affective Disorders*, vol. 169, no. 12, pp. 1496–1503, 2007.

[63] J. Plutzky, "Peroxisome proliferator-activated receptors as therapeutic targets in inflammation," *Journal of the American College of Cardiology*, vol. 42, no. 10, pp. 1764–1766, 2003.

[64] P. C. White, "Alterations of cortisol metabolism in human disorders," *Hormone Research in Pediatrics*, vol. 89, no. 5, pp. 320–330, 2018.
[65] M. C. Holmes, C. T. Abrahamsen, K. L. French, J. M. Patterson, J. J. Mullins, and J. R. Seckl, "The mother or the fetus? 11beta-hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids," The Journal of Neuroscience, vol. 26, no. 14, pp. 3840–3844, 2006.

[66] T. Fournier, V. Tsatsaris, K. Handschuh, and D. Evain-Brion, "PPARs and the placenta," Placenta, vol. 28, no. 2-3, pp. 65–76, 2007.

[67] P. He, Z. Chen, Q. Sun, Y. Li, H. Gu, and X. Ni, "Reduced expression of 11β-hydroxysteroid dehydrogenase type 2 in preeclamptic placentas is associated with decreased PPARγ but increased PPARα expression," Endocrinology, vol. 155, no. 1, pp. 299–309, 2014.

[68] L. Julan, H. Guan, J. P. van Beek, and K. Yang, "Peroxisome proliferator-activated receptor delta suppresses 11beta-hydroxysteroid dehydrogenase type 2 gene expression in human placental trophoblast cells," Endocrinology, vol. 146, no. 3, pp. 1482–1490, 2005.

[69] A. C. Campos, G. N. Vaz, V. M. Saito, and A. L. Teixeira, "Further evidence for the role of interferon-gamma on anxiety- and depressive-like behaviors: involvement of hippocampal neurogenesis and NGF production," Neuroscience Letters, vol. 578, pp. 100–105, 2014.

[70] R. Tükel, B. A. Arslan, B. A. Ertekin et al., "Decreased IFN-γ and IL-12 levels in panic disorder," Journal of Psychosomatic Research, vol. 73, no. 1, pp. 63–67, 2012.

[71] J. Fenimore and H. A. Young, "Regulation of IFN-γ expression," Advances in Experimental Medicine and Biology, vol. 941, pp. 1–19, 2016.

[72] P. Libby and J. Plutzky, "Inflammation in diabetes mellitus: role of peroxisome proliferator-activated Receptor-α and peroxisome proliferator-activated Receptor-γ agonists," The American Journal of Cardiology, vol. 99, no. 4, pp. 27–40, 2007.

[73] Y. Liu, J. Wang, S. Luo, Y. Zhan, and Q. Lu, "The roles of PPARγ and its agonists in autoimmune diseases: a comprehensive review," Journal of Autoimmunity, vol. 113, article 102510, 2020.

[74] Y. Okabayashi, S. Nagasaka, G. Kanzaki, N. Tsuboi, T. Yokoo, and A. Shimizu, "Group I innate lymphoid cells are involved in the progression of experimental anti-glomerular basement membrane glomerulonephritis and are regulated by peroxisome proliferator-activated receptor α," Kidney International, vol. 96, no. 4, pp. 942–956, 2019.

[75] H.-J. Park and J.-M. Choi, "Sex-specific regulation of immune responses by PPARs," Experimental & Molecular Medicine, vol. 49, no. 8, article e364, 2017.

[76] O. Y. Alshogran, A. A. Khalil, A. O. Oweis, S. M. Altawanbeh, and M. A. Y. Alqudah, "Association of brain-derived neurotrophic factor and interleukin-6 serum levels with depressive and anxiety symptoms in hemodialysis patients," General Hospital Psychiatry, vol. 53, pp. 25–31, 2018.

[77] E. Avolio, G. Fazzari, M. Mele et al., "Unpredictable chronic mild stress paradigm established effects of pro- and anti-inflammatory cytokine on neurodegeneration-linked depressive states in hamsters with brain endothelial damages," Molecular Neurobiology, vol. 54, no. 8, pp. 6446–6458, 2017.

[78] J. Lasselin, S. Elenbruch, M. Lekander et al., "Mood disturbance during experimental endotoxemia: predictors of state anxiety as a psychological component of sickness behavior," Brain, Behavior, and Immunity, vol. 57, pp. 30–37, 2016.

[79] B. Leonard and M. Maes, "Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression," Neuroscience and Biobehavioral Reviews, vol. 36, no. 2, pp. 764–785, 2012.

[80] Z. Zou, B. Zhou, Y. Huang, J. Wang, W. Min, and T. Li, "Differences in cytokines between patients with generalised anxiety disorder and panic disorder," Journal of Psychosomatic Research, vol. 133, article 109975, 2020.

[81] S. T. H. Lee, "Inflammation, depression, and anxiety disorder: a population-based study examining the association between interleukin-6 and the experiencing of depressive and anxiety symptoms," Psychiatry Research, vol. 285, article 112809, 2020.

[82] E.-Y. N. Wagner, M.-P. F. Stripoli, V. Ajdacic-Gross et al., "Generalized anxiety disorder is prospectively associated with decreased levels of interleukin-6 and adiponectin among individuals from the community," Journal of Affective Disorders, vol. 270, pp. 114–117, 2020.

[83] H. Chang, F. Zhao, X. Xie et al., "PPARα suppresses Th17 cell differentiation through IL-6/STAT3/ROtyR pathway in experimental autoimmune myocarditis," Experimental Cell Research, vol. 375, no. 1, pp. 22–30, 2019.

[84] G. Kökény, L. Calvier, E. Legchenko, P. Chouvarine, M. M. Mózes, and G. Hansmann, "PPARγ is a gatekeeper for extracellular matrix and vascular cell homeostasis," Current Opinion in Neurology and Hypertension, vol. 29, no. 2, pp. 171–179, 2020.

[85] Z. Kunicka, A. Kurzyńska, A. Szydłowska, B. Kaczynska, and J. Bogacka, "PPARβ/δ ligands regulate the expression of immune response mediators in the porcine endometrium - an in vitro study," Theriogenology, vol. 134, pp. 112–120, 2019.

[86] D. J. Haleem, Z. Haque, Q.-A. Inam, H. Ikram, and M. A. Haleem, "Behavioral, hormonal and central serotonin modulating effects of injected leptin," Peptides, vol. 74, pp. 1–8, 2015.

[87] M. E. Byrne, M. Tanoński-Kraff, M. Jaramillo et al., "Relationships of trait anxiety and loss of control eating with serum leptin concentrations among youth," Nutrients, vol. 11, no. 9, p. 2198, 2019.

[88] S. Cernea, E. Both, A. Huțanu, F. L. Şular, and A. L. Roiban, "Correlations of serum leptin and leptin resistance with depression and anxiety in patients with type 2 diabetes," Psychiatry and Clinical Neurosciences, vol. 73, no. 12, pp. 745–753, 2019.

[89] J. Liu, M. Guo, and X.-Y. Lu, "Leptin/LepRb in the ventral tegmental area mediates anxiety-related behaviors," The International Journal of Neuropsychopharmacology, vol. 19, no. 2, article pyr115, 2016.

[90] S. M. Tyree, R. G. K. Munn, and N. McNaughton, "Anxiolytic-like effects of leptin on fixed interval responding," Pharmacology, Biochemistry, and Behavior, vol. 148, pp. 15–20, 2016.

[91] L. V. d'Uscio, T. He, A. V. R. Santhanam, L.-J. Tai, R. M. Evans, and M. Haleem, "Behavioral, hormonal and central serotonin modulating effects of injected leptin," Peptides, vol. 74, pp. 1–8, 2015.

[92] A. Magadum and F. B. Engel, "PPARβ/δ: linking metabolism to regeneration," International Journal of Molecular Sciences, vol. 19, no. 7, p. 2013, 2018.
[93] K.-D. Wagner, M. Benchetrit, L. Bianchini, J.-F. Michiels, and N. Wagner, “Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) is highly expressed in liposarcoma and promotes migration and proliferation,” The Journal of Pathology, vol. 224, no. 4, pp. 575–588, 2011.

[94] R. Sah and T. D. Geraciotti, “Neuropeptide Y and posttraumatic stress disorder,” Molecular Psychiatry, vol. 18, no. 6, pp. 646–655, 2013.

[95] S. Sayed, N. T. Van Dam, S. R. Horn et al., “A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder,” The International Journal of Neuropsychopharmacology, vol. 21, no. 1, pp. 3–11, 2018.

[96] S. N. Schmeltzer, J. P. Herman, and R. Sah, “Neuropeptide Y (NPY) and posttraumatic stress disorder (PTSD): a translational update,” Experimental Neurology, vol. 284, pp. 196–210, 2016.

[97] K. Shiozaki, M. Kawabe, K. Karasuyama et al., “Neuropeptide Y deficiency induces anxiety-like behaviours in zebrafish (Danio rerio),” Scientific Reports, vol. 10, no. 1, p. 5913, 2020.

[98] J. T. Garretson, B. J. W. Teubner, K. L. Grove, S. N. Schmeltzer, J. P. Herman, and R. Sah, “Neuropeptide Y (NPY) and posttraumatic stress disorder (PTSD): a translational update,” Experimental Neurology, vol. 284, pp. 196–210, 2016.

[99] J. T. Garretson, B. J. W. Teubner, K. L. Grove, S. N. Schmeltzer, J. P. Herman, and R. Sah, “Neuropeptide Y (NPY) and posttraumatic stress disorder (PTSD): a translational update,” Experimental Neurology, vol. 284, pp. 196–210, 2016.

[100] N. Calvo, M. Cecchi, M. Kabbaj, S. J. Watson, and H. Akil, “Differential effects of social defeat in rats with high and low locomotor response to novelty,” Neuroscience, vol. 183, pp. 81–89, 2011.

[101] S. Hellwig and K. Domschke, “Anxiety in late life: an update on pathomechanisms,” Gerontology, vol. 65, no. 5, pp. 465–473, 2019.

[102] J. V. Zorn, R. R. Schür, M. P. Boks, R. S. Kahn, M. Joëls, and S. Hellwig and K. Domschke, “Anxiety in late life: an update on pathomechanisms,” Gerontology, vol. 65, no. 5, pp. 465–473, 2019.

[103] N. Bougarne, R. Paumelle, S. Caron et al., “PPARα blocks glucocorticoid receptor a-mediated transactivation but cooperates with the activated glucocorticoid receptor a for transrepression on NF-κB,” Proceedings National Academy of Sciences United States of America, vol. 106, no. 18, pp. 7397–7402, 2009.

[104] X. Chen, M. Li, W. Sun et al., “Peroxisome proliferator-activated receptor alpha agonist-induced down-regulation of hepatic glucocorticoid receptor expression in SD rats,” Biochemical and Biophysical Research Communications, vol. 368, no. 4, pp. 865–870, 2008.

[105] T. Varga, Z. Czimmerer, and L. Nagy, “PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1812, no. 8, pp. 1007–1022, 2011.

[106] G. Rando, C. K. Tan, N. Khaled et al., “Glucocorticoid receptor-PPARα axis in fetal mouse liver prepares neonates for milk lipid catabolism,” eLife, vol. 5, 2016.

[107] B. L. Parry, L. F. Martinez, E. L. Maurer, A. M. López, D. Sorenson, and C. J. Meliska, “Sleep, rhythms and women’s mood. Part I. Menstrual cycle, pregnancy and postpartum,” Sleep Medicine Reviews, vol. 10, no. 2, pp. 129–144, 2006.

[108] R. T. Chatterton, K. M. Vogelsong, Y. C. Lu, and G. A. Hugens, “Hormonal responses to psychological stress in men preparing for skydiving,” The Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 8, pp. 2503–2509, 1997.

[109] M. Sabariejo, M. J. Gómez, I. Morón et al., “Differential gene expression between inbred Roman high- (RHA-) and low- (RLA-) avoidance rats,” Neuroscience Letters, vol. 504, no. 3, pp. 265–270, 2011.

[110] B. König, C. Rauer, S. Rosenbaum, C. Brandsch, K. Eder, and G. I. Stangl, “Fasting upregulates PPARα target genes in brain and influences pituitary hormone expression in a PPARα dependent manner,” PPAR Research, vol. 2009, Article ID 801609, 9 pages, 2009.

[111] R. M. Tolón, A. I. Castillo, and A. Aranda, “Activation of the prolactin gene by peroxisome proliferator-activated receptor α appears to be DNA binding-independent,” The Journal of Biological Chemistry, vol. 273, no. 41, pp. 26652–26661, 1998.

[112] R. M. Tolón, A. I. Castillo, A. M. Jiménez-Lara, and A. Aranda, “Association with Ets-1 causes ligand- and AF2-independent activation of nuclear receptors,” Molecular and Cellular Biology, vol. 20, no. 23, pp. 8793–8802, 2000.

[113] C. Tomkiewicz, F. Muzeau, A. D. Edgar, R. Barouki, and M. Aggerbeck, “Opposite regulation of the rat and human cytotoxic aspartate aminotransferase genes by fibers,” Biochemical Pharmacology, vol. 67, no. 2, pp. 213–225, 2004.

[114] M. Postal, A. T. Lapa, N. A. Sinicato et al., “Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus,” Journal of Neuroinflammation, vol. 13, no. 1, p. 5, 2016.

[115] R. Hou, M. Garner, C. Holmes et al., “Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: case-controlled study,” Brain, Behavior, and Immunity, vol. 62, pp. 212–218, 2017.

[116] M. L. Camara, F. Corrigian, E. J. Jaehne et al., “TNF-α and its receptors modulate complex behaviours and neurotrophins in transgenic mice,” Psychoendoecrinology, vol. 38, no. 12, pp. 3102–3114, 2013.

[117] C. Giavarelli, I. Motta, S. Valente, and G. Pasquinelli, “Pharmacological (or synthetic) and nutritional agonists of PPAR-γ as candidates for cytokine storm modulation in COVID-19 disease,” Molecules, vol. 25, no. 9, p. 2076, 2020.

[118] A. Dutta and N. Sharma-Walia, “Curbing lipids: impacts on cancer and viral infection,” International Journal of Molecular Sciences, vol. 20, no. 3, p. 644, 2019.

[119] O. Y. Kytikova, J. M. Perelman, T. P. Novgorodtseva et al., “Peroxisome proliferator-activated receptors as a therapeutic target in asthma,” PPAR Research, vol. 2020, Article ID 8906968, 18 pages, 2020.

[120] Y. Ma, M. Shi, Y. Wang, and J. Liu, “PPARγ and its agonists in chronic kidney disease,” International Journal of Nephrology, vol. 2020, Article ID 2917474, 10 pages, 2020.

[121] N. Wagner and K.-D. Wagner, “PPAR beta/delta and the hallmarks of cancer,” Cell, vol. 9, no. 5, p. 1133, 2020.

[122] D. Li, J. Zheng, M. Wang et al., “Changes of TSPO-mediated mitophagy signaling pathway in learned helplessness mice,” Psychiatry Research, vol. 245, pp. 141–147, 2016.

[123] X.-B. Li, A. Liu, L. Yang et al., “Antidepressant-like effects of translocator protein (18 kDa) ligand ZBD-2 in mouse models.
of postpartum depression,” *Molecular Brain*, vol. 11, no. 1, p. 12, 2018.

[124] S. Taliani, I. Pugliesi, and F. Da Settimo, “Structural requirements to obtain highly potent and selective 18 kDa Translocator Protein (TSPO) Ligands,” *Current Topics in Medicinal Chemistry*, vol. 11, no. 7, pp. 860–886, 2011.

[125] L. Veenman and M. Gavish, “The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development,” *Pharmacology & Therapeutics*, vol. 110, no. 3, pp. 503–524, 2006.

[126] T. Barichello, L. R. Simões, A. Collodel et al., “The translocator protein (18kDa) and its role in neuropsychiatric disorders,” *Neuroscience and Biobehavioral Reviews*, vol. 83, pp. 183–199, 2017.

[127] R. Balon and V. Starcevic, “Role of benzodiazepines in anxiety disorders,” *Advances in Experimental Medicine and Biology*, vol. 1191, pp. 367–388, 2020.

[128] A. Batarseh and V. Papadopoulos, “Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states,” *Molecular and Cellular Endocrinology*, vol. 327, no. 1-2, pp. 1–12, 2010.

[129] M. Gazouli, Z.-X. Yao, N. Boujrad, J. C. Corton, M. Culty, and V. Papadopoulos, “Effect of peroxisome proliferators on Leydig cell peripheral-type benzodiazepine receptor gene expression, hormone-stimulated cholesterol transport, and steroidogenesis: role of the peroxisome proliferator-activator receptor α,” *Endocrinology*, vol. 143, no. 7, pp. 2571–2583, 2002.

[130] O. Petyunina, M. Kopytsya, I. Kuznetsov, and I. Vyshneva, “Prognostication of clinical outcomes after stemi: the role of vascular endothelial growth factor-A,” *Georgian Medical News*, vol. 279, pp. 79–86, 2018.

[131] T. Tomita, N. Yasui-Furukori, S. Tsuchimine, A. Kaneda, and S. Kaneko, “Relationships between vascular endothelial growth factor levels and temperament and character inventory traits in healthy Japanese subjects,” *Neuropsychobiology*, vol. 69, no. 1, pp. 1–5, 2014.

[132] C. Röhrl, U. Kaindl, I. Konecny et al., “Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells,” *Journal of Cancer Research and Clinical Oncology*, vol. 137, no. 1, pp. 29–39, 2011.

[133] R. Grau, C. Punzón, M. Fresno, and M. A. Iñiguez, “Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1,” *The Biochemical Journal*, vol. 395, no. 1, pp. 81–88, 2006.

[134] J. M. Spielberg, J. M. Schwarz, and M. A. Matyi, “Anxiety in transition: neuroendocrine mechanisms supporting the development of anxiety pathology in adolescence and young adulthood,” *Frontiers in Neuroendocrinology*, vol. 55, article 100791, 2019.

[135] S. P. A. Wolfensberger, D. J. Veltman, W. J. G. Hoogendijk, D. I. Boomsma, and E. J. C. de Geus, “Amygdala responses to emotional faces in twins discordant or concordant for the risk for anxiety and depression,” *NeuroImage*, vol. 41, no. 2, pp. 544–552, 2008.

[136] G.-Q. Chang, O. Karatayev, O. Lukatskaya, and S. F. Leibowitz, “Prenatal fat exposure and hypothalamic PPAR β/δ: possible relationship to increased neurogenesis of orexigenic peptide neurons,” *Peptides*, vol. 79, pp. 16–26, 2016.

[137] J. Yong, L. Yan, J. Wang, H. Xiao, and Q. Zeng, “Effects of compound 21, a non-peptide angiotensin II type 2 receptor agonist, on general anesthesia-induced cerebral injury in neonatal rats,” *Molecular Medicine Reports*, vol. 18, pp. 5337–5344, 2018.

[138] B. M. Flannery, J. L. Silverman, D. A. Bruun et al., “Behavioral assessment of NIH Swiss mice acutely intoxicated with tetramethylenedisulfotetramine,” *Neurotoxicology and Teratology*, vol. 47, pp. 36–45, 2015.

[139] N. Haji, G. Mandolesi, A. Gentile et al., “TNF-α-mediated anxiety in a mouse model of multiple sclerosis,” *Experimental Neurology*, vol. 237, no. 2, pp. 296–303, 2012.

[140] K. Sanchez, S. P. Guerin, and L. K. Fonken, “Anxiety in obesity: is neuroinflammation the critical link?,” *Brain, Behavior, and Immunity*, vol. 78, pp. 7–8, 2019.

[141] B. Willekens, G. Perrotta, P. Cras, and N. Cools, “Into the moment: does mindfulness affect biological pathways in multiple sclerosis?,” *Frontiers in Behavioral Neuroscience*, vol. 12, p. 103, 2018.

[142] D. Corbecki, R. Bobinski, and M. Dutka, “Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors,” *Inflammation Research*, vol. 68, no. 6, pp. 443–458, 2019.

[143] H. Shen, E. Oesterling, A. Stromberg, M. Toborek, R. Mac Donald, and B. Hennig, “Zinc deficiency induces vascular pro-inflammatory parameters associated with NF-kappaB and PPAR signaling,” *Journal of the American College of Nutrition*, vol. 27, no. 5, pp. 577–587, 2008.

[144] N. Martin, X. Ma, and D. Bernard, “Regulation of cellular senescence by retinoid X receptors and their partners,” *Mechanisms of Ageing and Development*, vol. 183, article 111113, 2019.

[145] J.-J. Zhou, J.-D. Ma, Y.-Q. Mo et al., “Down-regulating peroxisome proliferator-activated receptor-gamma activator-1 beta alleviates the proinflammatory effect of rheumatoid arthritis fibroblast-like synoviocytes through inhibiting extra-cellular signal-regulated kinase, p38 and nuclear factor-kappaB activation,” *Arthritis Research & Therapy*, vol. 16, no. 5, pp. 472, 2014.

[146] Y. Lin, M. Sun, S. M. Fuentes, C. D. Keim, T. Rothermel, and B. He, “Inhibition of interleukin-6 expression by the V protein of parainfluenza virus 5,” *Virology*, vol. 368, no. 2, pp. 262–272, 2007.

[147] W. Zou, A. Amcheslavsky, S. Takeshita, H. Drissi, and Z. Bar-Shavit, “TNF-alpha expression is transcriptionally regulated by RANK ligand,” *Journal of Cellular Physiology*, vol. 202, no. 2, pp. 371–378, 2005.

[148] L. Wang, J. Zhu, S. Shan et al., “Repression of interleukin-6 expression in T cells by Prospero-related homeobox protein,” *Cell Research*, vol. 18, no. 9, pp. 911–920, 2008.

[149] T. Maeda and S. Kishioka, “Chapter 13 PPAR and pain,” *International Review of Neurobiology*, vol. 85, pp. 165–177, 2009.

[150] R. A. Quintanilla, E. Utreras, and F. A. Cabezas-Opazo, “Role of PPAR γ in the differentiation and function of neurons,” *PPAR Research*, vol. 2014, Article ID 768594, 9 pages, 2014.

[151] A. Domi, S. Stopponi, E. Domi, R. Cicciocoppi, and N. Cannella, “Sub-dimensions of alcohol use disorder in alcohol preferring and non-prefering rats, a comparative study,” *Frontiers in Behavioral Neuroscience*, vol. 13, p. 3, 2019.
[152] J. D. Jones, S. D. Comer, V. E. Metz et al., “Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential,” *Pharmacology, Biochemistry, and Behavior*, vol. 163, pp. 90–100, 2017.

[153] T. Zimmermann, J. C. Bartsch, A. Beer et al., “Impaired anandamide/palmitoylethanolamide signaling in hippocampal glutamatergic neurons alters synaptic plasticity, learning, and emotional responses,” *Neuropsychopharmacology*, vol. 44, no. 8, pp. 1377–1388, 2019.

[154] E. Domi, S. Uhrig, L. Soverchia et al., “Genetic deletion of neuronal PPARγ enhances the emotional response to acute stress and exacerbates anxiety: an effect reversed by rescue of amygdala PPARγ function,” *The Journal of Neuroscience*, vol. 36, no. 50, pp. 12611–12623, 2016.

[155] K. Boes, V. Russmann, T. Ongerth et al., “Expression regulation and targeting of the peroxisome proliferator-activated receptor γ following electrically-induced status epilepticus,” *Neuroscience Letters*, vol. 604, pp. 151–156, 2015.

[156] E. Domi, F. F. Caputi, P. Romualdi et al., “Activation of PPARγ attenuates the expression of physical and affective nicotine withdrawal symptoms through mechanisms involving amygdala and hippocampus neurotransmission,” *The Journal of Neuroscience*, vol. 39, no. 49, pp. 9864–9875, 2019.

[157] J. C. Gaspar, B. N. Okine, A. Llorente-Berzal, M. Roche, and D. P. Finn, “Pharmacological blockade of PPAR isoforms increases conditioned fear responding in the presence of nociceptive tone,” *Molecules*, vol. 25, no. 4, article 1007, 2020.

[158] S. Sánchez-Iglesias, A. Fernández-Liste, C. Guillín-Amarelle et al., “Does seipin play a role in oxidative stress protection and peroxisome biogenesis? New insights from human brain autopsy,” *Neuroscience*, vol. 396, pp. 119–137, 2019.

[159] O. Okonkwo and A. Adeyinka, “Biochemistry, cholecystokinin (CCK),” in *StatPearls*, StatPearls Publishing, Treasure Island, FL, USA, 2020.

[160] M. Javanmard, J. Shlik, S. H. Kennedy, F. J. Vaccarino, S. Houle, and J. Bradwejn, “Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points,” *Biological Psychiatry*, vol. 45, no. 7, pp. 872–882, 1999.

[161] M. Kellner, “Experimental panic provocation in healthy man: a translational role in anti-panic drug development?” *Dialogues in Clinical Neuroscience*, vol. 13, no. 4, pp. 485–493, 2011.

[162] P. Zwanzger, K. Domshke, and J. Bradwejn, “Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin,” *Depression and Anxiety*, vol. 29, no. 9, pp. 762–774, 2012.

[163] J. Andre, B. Zeau, M. Pohl, F. Cesselin, J.-J. Benoliel, and C. Becker, “Involvement of cholecystokininergic systems in anxiety-induced hyperalgesia in male rats: behavioral and biochemical studies,” *The Journal of Neuroscience*, vol. 25, no. 35, pp. 7896–7904, 2005.

[164] Y. Clement and G. Chapouthier, “Biological bases of anxiety,” *Neuroscience and Biobehavioral Reviews*, vol. 22, no. 5, pp. 623–633, 1998.

[165] C. Del Boca, P. E. Lutz, J. Le Merrer, P. Koebel, and B. L. Kieffer, “Cholecystokinin knock-down in the basolateral amygdala has anxioiytic and antidepressant-like effects in mice,” *Neuroscience*, vol. 218, pp. 185–195, 2012.

[166] F. Noble, S. A. Wank, J. N. Crawley et al., “International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors,” *Pharmacological Reviews*, vol. 51, no. 4, pp. 745–781, 1999.

[167] S. Ballaz, “The unappreciated roles of the cholecystokinin receptor CCK (1) in brain functioning,” *Reviews in the Neurosciences*, vol. 28, no. 6, pp. 573–585, 2017.

[168] L. Lu, B. Zhang, Z. Liu, and Z. Zhang, “Reactivation of cocaine conditioned place preference induced by stress is reversed by cholecystokinin-B receptors antagonist in rats,” *Brain Research*, vol. 954, no. 1, pp. 132–140, 2002.

[169] G. R. Wunderlich, R. Raymond, N. J. DeSousa, J. N. Nobrega, and F. J. Vaccarino, “Decreased CCK (B) receptor binding in rat amygdala in animals demonstrating greater anxiety-like behavior,” *Psychopharmacology*, vol. 164, no. 2, pp. 193–199, 2002.

[170] A. P. Nesterova, E. A. Klimov, M. Zharkova et al., “Introduction,” in *Disease Pathways*, pp. 3–32, Elsevier, 2020.

[171] L. Katsouri, C. Parr, N. Bogdanovic, M. Willem, and M. Sastre, “PPAR co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism,” *Journal of Alzheimer’s Disease*, vol. 25, no. 1, pp. 151–162, 2011.

[172] S. Takai, D. Jin, M. Kimura et al., “Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats,” *Hypertension Research*, vol. 30, no. 12, pp. 1231–1237, 2007.

[173] A. Kaloudi, B. A. Nock, E. Lymeris et al., “In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111) in radioligands,” *Nuclear Medicine and Biology*, vol. 42, no. 11, pp. 824–832, 2015.

[174] P. Dubreuil, P. Fulcrand, M. Rodriguez, H. Fulcrand, J. Laur, and J. Martinez, “Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide,” *Biochemical Journal*, vol. 262, no. 1, pp. 125–130, 1989.

[175] K. A. Zuzel, C. Rose, and J. C. Schwartz, “Assessment of the role of "enkephalinase" in cholecystokinin inactivation,” *Neuroscience*, vol. 15, no. 1, pp. 149–158, 1985.